Hunan Shentaichun Pharmaceutical Co., Ltd.

Main research purpose: This study investigates the pharmacokinetic characteristics of theophylline sustained-release tablets (test preparation, specification: 100 mg) provided by Hunan Shentaichun Pharmaceutical Co., Ltd. and theophylline sustained-release tablets (reference preparation R, trade name: UNICONTM, specification: 100 mg) certified by Nichiyo Co., Ltd. under the same conditions when taken orally once in a single dose in healthy subjects under fasting and postprandial conditions, evaluates the bioequivalence between the two preparations, and provides a basis for the consistency evaluation of the test preparation. Secondary research purpose: Observe the safety of the test preparation theophylline sustained-release tablets (specification: 100 mg) and the reference preparation theophylline sustained-release tablets (trade name: UNICONTM, specification: 100 mg) taken orally once in a single dose in healthy subjects under fasting and postprandial conditions

Main study purpose This study investigates the pharmacokinetic characteristics of theophylline sustained-release tablets (test preparation, specification: 100 mg) produced by Hunan Shentaichun Pharmaceutical Co., Ltd. and theophylline sustained-release tablets (reference preparation R, trade name: UNICONTM, specification: 100 mg) certified by Nichia Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions, evaluates the bioequivalence between the two preparations, and provides a basis for the consistency evaluation of the test preparation. Secondary study purpose To observe the safety of the test preparation theophylline sustained-release tablets (specification: 100 mg) and the reference preparation theophylline sustained-release tablets (trade name: UNICONTM, specification: 100 mg) in healthy subjects under fasting and postprandial conditions.

Main study purpose This study investigated the pharmacokinetic characteristics of theophylline sustained-release tablets (test preparation, specification: 100 mg) produced by Hunan Shentaichun Pharmaceutical Co., Ltd. and theophylline sustained-release tablets (reference preparation R, trade name: UNICONTM, specification: 100 mg) certified by Nichiyo Co., Ltd. under the same conditions after a single oral administration to healthy subjects under fasting and postprandial conditions, evaluated the bioequivalence between the two preparations, and provided a basis for the consistency evaluation of the test preparation. Secondary study purpose Observe the safety of the test preparation theophylline sustained-release tablets (specification: 100 mg) and the reference preparation theophylline sustained-release tablets (trade name: UNICONTM, specification: 100 mg) taken orally as a single dose of 100 mg in healthy subjects under fasting and postprandial conditions.